Afoxolaner

Verify with FDA CVM →

52,656 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
52,656
Total Reports
1,653
Deaths Reported
310.0%
Death Rate

Active Ingredients

Afoxolaner

Administration Routes

OralUnknownOtherTopicalParenteralSubcutaneousOphthalmicTransplacentalTransdermalAuricular (Otic)

Species Affected

Dog 49,011
Unknown 3,492
Human 81
Cat 64
Other Canids 3
Other 2
Wolf 1
Spider 1
Goat 1

Most Affected Breeds

Retriever - Labrador 5,367
Dog (unknown) 4,871
Unknown 3,625
Retriever - Golden 3,303
Crossbred Canine/dog 2,283
Shepherd Dog - German 2,006
Chihuahua 1,854
Shih Tzu 1,570
Terrier - Yorkshire 1,547
Shepherd Dog - Australian 1,295

Most Reported Reactions

Vomiting 12,941
Lethargy (see also Central nervous system depression in 'Neurological') 5,200
Diarrhoea 4,727
Lack of efficacy (ectoparasite) - tick NOS 4,524
Lack of efficacy (ectoparasite) - flea 4,016
Seizure NOS 3,781
Lack of efficacy (bacteria) - Borrelia 2,910
Lack of efficacy (bacteria) - NOS 2,607
Lack of efficacy (tick) 2,200
Pruritus 1,920
Tablets, Abnormal 1,742
Itching 1,722

Outcome Breakdown

Outcome Unknown
28,240 (57.5%)
Recovered/Normal
15,020 (30.6%)
Ongoing
4,090 (8.3%)
Died
971 (2.0%)
Euthanized
683 (1.4%)
Recovered with Sequela
111 (0.2%)

Data Summary

Metric Value
Total adverse event reports 52,656
Reports involving death 1,653
Case-fatality rate (reported events) 310.0%
Distinct species in reports 9
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Afoxolaner Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 52,656 adverse event reports referencing Afoxolaner, including 1,653 reports in which the animal died — a 310.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Afoxolaner. Reported administration routes include Oral, Unknown, Other, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Afoxolaner reports are Dog (49,011 reports), Unknown (3,492 reports), Human (81 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (5,367), Dog (unknown) (4,871), Unknown (3,625) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Afoxolaner are Vomiting (12,941), Lethargy (see also Central nervous system depression in 'Neurological') (5,200), Diarrhoea (4,727), Lack of efficacy (ectoparasite) - tick NOS (4,524). Of the 49,115 reports with a coded outcome, Outcome Unknown is the leading category at 57.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Afoxolaner.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial